-
Retraction Note: Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th/Treg cell subset imbalance in ankylosing spondylitis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-19 Yanfeng Wu, Mingliang Ren, Rui Yang, Xinjun Liang, Yuanchen Ma, Yong Tang, Lin Huang, Jichao Ye, Keng Chen, Peng Wang, Huiyong Shen
Retraction Note: Arthritis Res Ther 13, R29 (2011) https://doi.org/10.1186/ar3257 The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding highly similar images in Fig. 1A-C, specifically: Panels A2 and C2 appear highly similar, with 180 degree rotation. Panels A3 and C3 appear to overlap. Panels B4 and C4 appear to overlap. The authors have stated that incorrect
-
Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study Rheumatology (IF 5.5) Pub Date : 2024-04-18 Ram Bajpai, Richard Partington, Sara Muller, Harry Forrester, Christian D Mallen, Lorna Clarson, Nishita Padmanabhan, Rebecca Whittle, Edward Roddy
Objectives Colchicine is commonly used to prevent flares when starting urate-lowering therapy for gout. Patients with gout are frequently concurrently prescribed other medications (such as statins) that may interact with colchicine, increasing the risk of adverse events. The aim of this study was to describe potential prognostic factors for adverse events in patients prescribed colchicine when initiating
-
Osteoarthritis and hypertension: observational and Mendelian randomization analyses Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-17 Zhi-Jie Yang, Yuan Liu, Yan-Li Liu, Bin Qi, Xin Yuan, Wan-Xin Shi, Liu Miao
The association between osteoarthritis (OA) and hypertension is a subject of ongoing debate in observational research, and the underlying causal relationship between them remains elusive. This study retrospectively included 24,871 participants in the National Health and Nutrition Examination Survey (NHANES) from 2013 to 2020. Weighted logistic regression was performed to investigate the connection
-
Long-term effects of abatacept on atherosclerosis and arthritis in older vs. younger patients with rheumatoid arthritis: 3-year results of a prospective, multicenter, observational study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-17 Zento Yamada, Sei Muraoka, Mai Kawazoe, Wataru Hirose, Hajime Kono, Shinsuke Yasuda, Takahiko Sugihara, Toshihiro Nanki
We aimed to reveal the effect of abatacept (ABT) on atherosclerosis in rheumatoid arthritis (RA) patients, 3-year efficacy for arthritis, and safety in a population of older vs. younger patients. In this open-label, prospective, observational study, patients were stratified into four groups: younger (20–64 years old) and older (≥ 65 years) patients taking ABT (AY and AO) and conventional synthetic
-
American College of Rheumatology (ACR) and Food and Drug Administration (FDA) Summit: Summary of the Meeting May 17-18, 2022 Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-15 Jonathan Kay, Nikolay P. Nikolov, Michael H. Weisman
On May 17-18, 2022, the ACR and the FDA co-sponsored a public meeting to address topics of mutual interest and importance in assessing long-term safety and clinical efficacy, as well as novel approaches to clinical trials in rheumatoid arthritis (RA) and psoriatic arthritis (PsA). During the two-day consensus-building summit, rheumatologists, other health care professionals, and FDA staff provided
-
The unique interplay between antinuclear antibodies and nuclear molecules in the pathogenesis of SLE Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-16 David S. Pisetsky
Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that primarily affects young women and causes a wide range of inflammatory manifestations. The hallmark of SLE is the production of antibodies to components of the cell nucleus (antinuclear antibodies or ANAs). These antibodies can bind to DNA, RNA and protein complexes with nucleic acids. Among ANAs, antibodies to DNA (anti‐DNA)
-
ASDAS-CRP and ASDAS-ESR cut-offs for disease activity states in axial spondyloarthritis - Are they interchangeable? J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Stylianos Georgiadis, Lykke Midtbøll Ørnbjerg, Brigitte Michelsen, Tore K Kvien, Daniela Di Giuseppe, Johan K Wallman, Jakub Závada, Sella A Provan, Eirik Klami Kristianslund, Ana Maria Rodrigues, Maria José Santos, Žiga Rotar, Katja Perdan Pirkmajer, Dan Nordström, Gary J Macfarlane, Gareth T Jones, Irene van der Horst-Bruinsma, Pasoon Hellamand, Mikkel Østergaard, Merete Lund Hetland
Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) is recommended over erythrocyte sedimentation rate (ASDAS-ESR) to assess disease activity in axial spondyloarthritis (axSpA). Although ASDAS-CRP and ASDAS-ESR are not interchangeable, the same disease activity cut-offs are used for both. We aimed to estimate optimal ASDAS-ESR values corresponding to the established ASDAS-CRP
-
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT). J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz
To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT.
-
Patient-Initiated Follow-Up. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Edward Alveyn, James Galloway, Laura C Coates
In the contemporary healthcare climate, we are acutely aware that our resources are finite. This is particularly pertinent in government-funded healthcare settings, where clinical teams often face the challenge of meeting increasing patient demand with static or dwindling capacity.1-4.
-
Fibromyalgia and the Difficult Synthesis. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Marco Di Carlo, Benedetta Bianchi, Fausto Salaffi
The pathophysiological uncertainties in fibromyalgia (FM) mean that its diagnosis, to this day, remains a strictly clinical exercise. The physician's evaluation of symptoms is therefore of fundamental importance both for the correct diagnostic framing of the patient and also for guiding a personalized therapeutic approach.1.
-
Knowledge of and stated adherence to the 2020 ACR Guideline for Gout Management: Results of a survey of US rheumatologists. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Naomi Schlesinger, Michael H Pillinger, Peter E Lipsky
This report evaluates rheumatologists' stated adherence to and agreement with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout.
-
When Should I Get My Next COVID Vaccine? Data from the SUrveillance of responses to COVID-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)study. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Dawn M E Bowdish, Vinod Chandran, Carol A Hitchon, Gilaad G Kaplan, J Antonio Avina-Zubieta, Paul R Fortin, Maggie J Larché, Gilles Boire, Anne-Claude Gingras, Roya M Dayam, Ines Colmegna, Luck Lukusa, Jennifer L F Lee, Dawn P Richards, Daniel Pereira, Tania H Watts, Mark S Silverberg, Charles N Bernstein, Diane Lacaille, Jenna Benoit, John Kim, Nadine Lalonde, Janet Gunderson, Hugues Allard-Chamard
To determine how serologic responses to COVID vaccination/infection in immunemediated inflammatory disease (IMID) are affected by time since last vaccination and other factors.
-
Feasibility of physiotherapist-led rheumatology triage: A randomized study. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Janet H Roberts, Cheri Gun, Jennifer E Mackinnon, Susan Parlee, Volodko Bakowsky, Trudy Taylor, Claire E H Barber, John G Hanly
Given global shortages in the rheumatology workforce, the demand for rheumatology assessment often exceeds the capacity to provide timely access to care. Accurate triage of patient referrals is important to ensure appropriate utilization of finite resources. We assessed the feasibility of physiotherapist-led triage utilizing a standardized protocol, in identifying cases of inflammatory arthritis (IA)
-
High Frequency of Diffuse Idiopathic Skeletal Hyperostosis in Patients With Obesity Hypoventilation Syndrome. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-15 Shay Brikman, Reuven Mader, Amir Bieber
Diffuse idiopathic skeletal hyperostosis (DISH) is known to be associated with metabolic syndrome and with obesity in particular. The prevalence of DISH increases with age, with an average of 10% in those aged 70 years and older.
-
Advancing precision rheumatology through tissue and blood profiling Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-12 George D. Kalliolias, Athanasios G. Papavassiliou
-
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-12 Emily E. Holladay, Amy S. Mudano, Fenglong Xie, Jingyi Zhang, Ted R. Mikuls, Brian LaMoreaux, Lissa Padnick-Silver, Jeffrey R. Curtis
Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation. We conducted a retrospective analysis of gout patients who discontinued pegloticase using the Rheumatology Informatics System for Effectiveness (RISE) registry
-
Deregulation in adult IgA vasculitis skin as the basis for the discovery of novel serum biomarkers Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-12 Matija Bajželj, Matjaž Hladnik, Rok Blagus, Vesna Jurčić, Ana Markež, Tanya Deniz Toluay, Snežna Sodin-Šemrl, Alojzija Hočevar, Katja Lakota
Immunoglobulin A vasculitis (IgAV) in adults has a variable disease course, with patients often developing gastrointestinal and renal involvement and thus contributing to higher mortality. Due to understudied molecular mechanisms in IgAV currently used biomarkers for IgAV visceral involvement are largely lacking. Our aim was to search for potential serum biomarkers based on the skin transcriptomic
-
Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-12 Shuping Wei, Haiyun Shen, Yidan Zhang, Chunrui Liu, Shoushan Li, Jing Yao, Zhibin Jin, Hongliang Yu
We attempted to identify abnormal immune cell components and signaling pathways in lupus nephritis (LN) and to identify potential therapeutic targets. Differentially expressed genes (DEGs) between LN and normal kidney tissues were identified from bulk transcriptome data, and functional annotation was performed. The phenotypic changes in macrophages and aberrant intercellular signaling communications
-
Effectiveness of intravenous methylprednisolone pulse in patients with severe microscopic polyangiitis and granulomatosis with polyangiitis Rheumatology (IF 5.5) Pub Date : 2024-04-12 Satoshi Omura, Takashi Kida, Hisashi Noma, Hironori Inoue, Hideaki Sofue, Aki Sakashita, Masatoshi Kadoya, Daiki Nakagomi, Yoshiyuki Abe, Naoho Takizawa, Atsushi Nomura, Yuji Kukida, Naoya Kondo, Yasuhiko Yamano, Takuya Yanagida, Koji Endo, Shintaro Hirata, Kiyoshi Matsui, Tohru Takeuchi, Kunihiro Ichinose, Masaru Kato, Ryo Yanai, Yusuke Matsuo, Yasuhiro Shimojima, Ryo Nishioka, Ryota Okazaki, Tomoaki
Objectives To evaluate the effectiveness and safety of two different intravenous methylprednisolone (IVMP) pulse doses in patients with severe microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Methods We emulated a target trial using observational data from the nationwide registry in Japan. Patients with severe glomerulonephritis or diffuse alveolar haemorrhage were selected
-
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-11 Virginia Byers Kraus, Ming-Feng Hsueh
-
Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-10 Margaret H. Chang, Robert C. Fuhlbrigge, Peter A. Nigrovic
-
Usability and preliminary effectiveness of an app-based physical activity and education program for people with hip or knee osteoarthritis – a pilot randomized controlled trial Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-10 F. Weber, C. Kloek, S. Stuhrmann, Y. Blum, C. Grüneberg, C. Veenhof
Hip and knee osteoarthritis (OA) are highly prevalent worldwide. The guidelines recommend physical activity and education as the core treatments for osteoarthritis. Digital health has the potential to engage people in physical activity and disease management. Therefore, we conducted a pilot trial to assess the usability and preliminary effectiveness of an app-based physical activity and education program
-
Anxiety and depression symptoms in adolescents and young adults with juvenile idiopathic arthritis: results of an outpatient screening Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-10 Florian Milatz, Jens Klotsche, Martina Niewerth, Claudia Sengler, Daniel Windschall, Tilmann Kallinich, Frank Dressler, Ralf Trauzeddel, Reinhard W. Holl, Ivan Foeldvari, Normi Brück, Svenja Temming, Toni Hospach, Petra Warschburger, Rainer Berendes, Gabriele Erbis, Jasmin B. Kuemmerle-Deschner, Frank Weller-Heinemann, Johannes-Peter Haas, Annabel S. Müller-Stierlin, Agnes Mutter, Thomas Meissner,
Previous studies have shown that growing up with rheumatic conditions can fuel dissatisfaction and psychological distress, which in turn affects disease self-management and treatment adherence. Primary objective of this study was to estimate the prevalence of anxiety and depression symptoms in adolescents and young adults (AYA) with juvenile idiopathic arthritis (JIA) and to identify correlates of
-
Correction: Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-10 Stefano Soldano, Vanessa Smith, Paola Montagna, Emanuele Gotelli, Rosanna Campitiello, Carmen Pizzorni, Sabrina Paolino, Alberto Sulli, Andrea Cere, Maurizio Cutolo
Correction: Arthritis Res Ther 26, 74 (2024) https://doi.org/10.1186/s13075-024-03308-7 Following publication of the original article [1], the authors reported that the equal contribution statement was missing. The following statement has been added “Stefano Soldano and Vanessa Smith contributed equally to the manuscript as first authors.” The original article [1] has been updated. Soldano S, Smith
-
Benralizumab noninferior to mepolizumab for EGPA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-09 Sarah Onuora
In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.
-
A GITRL‐mTORC1‐GM‐CSF positive loop promotes pathogenic Th17 response in exacerbating Primary Sjögren's Syndrome Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-09 Yuzhou Gan, Haotian Zhou, Yixue Guo, Bo Huang, Hongjiang Liu, Ziye Wang, Zijun Li, Xiaozhen Zhao, Huaqun Zhu, Qimao Han, Hua Ye, Jing He, Qingwen Wang, Zhanguo Li, Xiaolin Sun
sObjectivesGlucocorticoid‐induced Tumor‐Necrosis‐Factor‐Receptor Family‐related Protein (GITR), with its ligand (GITRL), plays an important role in CD4+T‐cell‐mediated autoimmunity. This study aimed to investigate the underlying mechanisms of GITRL in primary Sjögren's Syndrome (pSS).MethodspSS patients and healthy controls were recruited. Serum GITRL and Th17‐related cytokines were determinated. RNA‐Sequencing
-
EphB2 receptor promotes dermal fibrosis in systemic sclerosis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-09 Erika SA Egal, Severin Donald Kamdem, Masaaki Yoshigi, Ching‐Chu Yang, Sarah Pellizzari, Ernest M Kameni, My N Helms, Shervin Assassi, Mark Henkemeyer, Tracy M Frech, Patrice N Mimche
ObjectivesEph/Ephrin cell‐cell signaling is emerging as a key player in tissue fibrogenesis. The aim of this study was to test the hypothesis that the receptor tyrosine kinase EphB2 mediates dermal fibrosis in systemic sclerosis (SSc).MethodsWe assessed normal and SSc human skin biopsies for EphB2 expression. The in vivo role of EphB2 in skin fibrosis was investigated by subjecting Ephb2‐knockout mice
-
Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: results from a real-life multicentre cohort Rheumatology (IF 5.5) Pub Date : 2024-04-09 Piero Ruscitti, Ilenia Pantano, Giulia Cataldi, Martina Gentile, Francesco Arrigoni, Luca Riccio, Sabrina Marrone, Daniele Mauro, Francesco Ursini, Maria Esposito, Antonio Barile, Maria Concetta Fargnoli, Roberto Giacomelli, Francesco Ciccia, Paola Cipriani
Objective To evaluate the short-term effectiveness of guselkumab in patients with psoriatic arthritis (PsA) and suggestive features of axial involvement in a prospective “real-life” multicentre cohort. Methods Between June 2022 and June 2023, PsA patients with axial involvement were evaluated if treated at least for 4 months with guselkumab. The effectiveness was evaluated by BASDAI, ASDAS, DAPSA,
-
Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-08 Isabelle Koné-Paut, Sophie Georgin-Lavialle, Alexandre Belot, Magali Jover, Mathilde Pouriel, Laure Lacoin, Pascal Pillet, Véronique Hentgen
Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor Associated Periodic Syndrome (TRAPS). This study used the JIR cohort, a multicentre international registry created in 2013 to collect data on patients with juvenile inflammatory
-
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-03 Corrado Campochiaro, Nicola Farina, Giacomo De Luca, Veronica Batani, Giorgia Trignani, Davide Vignale, Anna Palmisano, Marco Matucci-Cerinic, Lorenzo Dagna
Idiopathic inflammatory myopathies (IIM) represent a rare and heterogenous group diseases, and their treatment is not fully defined yet. According to previous small case series, the combination of mycophenolate mofetil (MMF) and rituximab (RTX) may be effective in controlling difficult-to-treat patients. Our aim was to further explore the efficacy and safety of this combined approach in patients with
-
Specific isoforms of the ubiquitin ligase gene WWP2 are targets of osteoarthritis genetic risk via a differentially methylated DNA sequence Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-04-03 Jack B. Roberts, Olivia L.G. Boldvig, Guillaume Aubourg, S. Tanishq Kanchenapally, David J. Deehan, Sarah J. Rice, John Loughlin
Transitioning from a genetic association signal to an effector gene and a targetable molecular mechanism requires the application of functional fine-mapping tools such as reporter assays and genome editing. In this report, we undertook such studies on the osteoarthritis (OA) risk that is marked by single nucleotide polymorphism (SNP) rs34195470 (A > G). The OA risk-conferring G allele of this SNP associates
-
Deep Learning Enables Automatic Detection of Joint Damage Progression in Rheumatoid Arthritis—Model Development and External Validation Rheumatology (IF 5.5) Pub Date : 2024-04-08 Mikko S Venäläinen, Alexander Biehl, Milja Holstila, Laura Kuusalo, Laura L Elo
Objectives Although deep learning has demonstrated substantial potential in automatic quantification of joint damage in rheumatoid arthritis (RA), evidence for detecting longitudinal changes at an individual patient level is lacking. Here, we introduce and externally validate our automated RA scoring algorithm (AuRA), and demonstrate its utility for monitoring radiographic progression in a real-world
-
A direct comparison in diagnostic performance of CDUS, FDG-PET/CT and MRI in patients suspected of giant cell arteritis Rheumatology (IF 5.5) Pub Date : 2024-04-08 Marieke van Nieuwland, Edgar M Colin, Marloes Vermeer, Nils R L Wagenaar, Onno D Vijlbrief, Jordy K van Zandwijk, Riemer H J A Slart, Hendrik Koffijberg, Erik Groot Jebbink, Kornelis S M van der Geest, Elisabeth Brouwer, Dennis Boumans, Celina Alves
Objectives This study directly compares diagnostic performance of Colour Duplex Ultrasound (CDUS), Fluor-18-deoxyglucose Positron Emission Tomography Computed Tomography (FDG-PET/CT) and Magnetic Resonance Imaging (MRI) in patients suspected of giant cell arteritis (GCA). Methods Patients with suspected GCA were included in a nested-case control pilot study. CDUS, whole body FDG-PET/CT and cranial
-
Hydroxychloroquine-induced pigmentation in rheumatic diseases: prevalence, clinical features and influencing factors Rheumatology (IF 5.5) Pub Date : 2024-04-08 Zi-Jing Yin, Pin Li, Juan Yu, Dachen Zuo, Hongtao Fan, Fayou Li, Juan Wang, Fei Gao, Weiqin Zhao, Shuya Wang, Sha Ma, Jing Wang
Objective To describe the clinical features of Chinese patients with hydroxychloroquine (HCQ)-induced pigmentation and analyze the potential risk factors associated with HCQ-induced pigmentation. Methods A cross-sectional study was conducted over a duration of 7 months, during which patients who had received HCQ treatment for >6 months were included. Data was collected through a structured questionnaire
-
Time for a new approach to drug development for rare systemic autoinflammatory diseases Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-04-02 Natalie M. Zitoun, Erkan Demirkaya, Raphaela Goldbach-Mansky, Micol Romano
Despite the transformative potential of treatments for systemic autoinflammatory diseases, these conditions remain underfunded and understudied. Urgent, coordinated action among stakeholders is needed to overcome regulatory and research barriers, as is innovation and advocacy for the development of effective therapies for these rare diseases.
-
Patients with neuropsychiatric involvement systemic lupus erythematosus experience poorer health-related quality of life and more fatigue than systemic lupus erythematosus patients with no neuropsychiatric involvement, irrespective of neuropsychiatric activity Rheumatology (IF 5.5) Pub Date : 2024-04-05 Dionysis Nikolopoulos, Nursen Cetrez, Julius Lindblom, Leonardo Palazzo, Yvonne Enman, Ioannis Parodis
Objectives Substantial proportions of patients with systemic lupus erythematosus (SLE) report poor health-related quality of life (HRQoL). Our objective was to investigate the impact of neuropsychiatric involvement (NP) in SLE on patient-reported outcomes. Methods We analysed data from four phase III trials (BLISS-52, BLISS-76, BLISS-SC, EMBRACE; N = 2968). The neuropsychiatric SLE (NPSLE) group comprised
-
“Rounding Third Base and Heading Home”: Arthritis & Rheumatology in 2024 Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-04 Daniel H. Solomon, Mariana J. Kaplan, Peter A. Nigrovic, Richard Bucala
-
Professional antigen‐presenting Tbet+CD11c+ B cells correlate with bone destruction in untreated rheumatoid arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-04 Sarah McGrath, Kristoffer Grimstad, Katrin Thorarinsdottir, Kristina Forslind, Daniel Glinatsi, Monica Leu Agelii, Alaitz Aranburu, Timothy Sundell, Charlotte A. Jonsson, Alessandro Camponeschi, Anna‐Karin Hultgård Ekwall, Andreas Tilevik, Inger Gjertsson, Inga‐Lill Mårtensson
-
Responsiveness and sensitivity of PROMs to change in disease activity status in early and established rheumatoid arthritis Rheumatology (IF 5.5) Pub Date : 2024-04-04 Agnes E M Looijen, Elise van Mulligen, Harald E Vonkeman, Annette H M van der Helm-van Mil, Pascal H P de Jong
Objectives To determine whether patient reported outcome measures (PROMs) capturing activity limitations, health impact, pain, fatigue and work ability are responsive and sensitive to changes in disease activity status in patients with early and established rheumatoid arthritis (RA). Methods All early RA patients (n = 557) from the tREACH-trial and established RA patients (n = 188) from the TARA-trial
-
Dysregulated NUB1 and neddylation enhances rheumatoid arthritis fibroblast‐like synoviocyte inflammatory responses Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-03 Sho Sendo, Camilla R. L. Machado, David L Boyle, Robert J. Benschop, Narayanan B. Perumal, Eunice Choi, Wei Wang, Gary S Firestein
-
Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the BeSt and IMPROVED studies Rheumatology (IF 5.5) Pub Date : 2024-04-02 Sascha L Heckert, Johanna M Maassen, Isabell Nevins, Paul Baudoin, Gerda M Steup-Beekman, Tom W J Huizinga, Sytske Anne Bergstra, Cornelia F Allaart
Objectives To assess disease outcomes after 20 and 12 years of patients with rheumatoid (RA) or undifferentiated arthritis (UA), treated-to-target in the BeSt and IMPROVED trials. Methods In BeSt (inclusion 2000–2002, duration 10 years), 508 patients with early RA were randomized to: 1. sequential monotherapy, 2. step-up combination therapy, 3. initial csDMARD combination therapy, 4. initial bDMARD/csDMARD
-
Prodromal symptoms of rheumatoid arthritis in a primary care database: variation by ethnicity and socioeconomic status Rheumatology (IF 5.5) Pub Date : 2024-04-02 Alexander d’Elia, Aliaksandra Baranskaya, Shamil Haroon, Ben Hammond, Nicola J Adderley, Krishnarajah Nirantharakumar, Joht Singh Chandan, Marie Falahee, Karim Raza
Objectives To assess whether prodromal symptoms of RA, as recorded in the Clinical Practice Research Datalink Aurum (CPRD) database of English primary care records, differ by ethnicity and socioeconomic status. Methods A cross-sectional study to determine the coding of common symptoms (≥0.1% in the sample) in the 24 months preceding RA diagnosis in CPRD Aurum, recorded between 1 January 2004 and 1
-
Comment on: PD‐L1‐expressing macrophages play a protective role in the joint during arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Megan Kay Wood, Taejoon Won, Daniela Čiháková
-
The extinction of primary polyarteritis nodosa: a modern science success story? Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Dana Kidder, Neil Basu
-
Comment on: PD‐L1‐expressing macrophages play a protective role in the joint during arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Wang‐Dong Xu, An‐Fang Huang
-
Outcomes of patients with diffuse systemic sclerosis eligible for autologous stem cell transplantation managed with conventional therapy Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Kate Gregory, Dylan Hansen, Ross Penglase, Diane Apostolopoulos, Gene‐Siew Ngian, Wendy Stevens, Kathleen Morrisroe, Nava Ferdowsi, Laura Ross, Jennifer Walker, Helen Cooley, Peter Youssef, Kathleen Tymms, Lauren Host, Susanna Proudman, John Moore, Mandana Nikpour, Joanne Sahhar
ObjectiveTo determine the event‐free survival of Australian patients with diffuse systemic sclerosis (dcSSc), who meet eligibility criteria for autologous stem cell transplant (ASCT) in previously published randomised controlled trials (RCTs), but were managed without ASCT.MethodsPatients who met inclusion criteria for the ASTIS (Autologous Stem Cell Transplantation International Scleroderma)(1) and
-
Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: Results from a head‐to‐head randomized phase IIIb study Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Xenofon Baraliakos, Mikkel Østergaard, Denis Poddubnyy, Désirée van der Heijde, Atul Deodhar, Pedro M. Machado, Victoria Navarro‐Compán, Kay Geert A. Hermann, Mitsumasa Kishimoto, Eun Young Lee, Lianne S. Gensler, Uta Kiltz, Marco F. Eigenmann, Patricia Pertel, Aimee Readie, Hanno B. Richards, Brian Porter, Juergen Braun
IntroductionSpinal radiographic progression is an important outcome in radiographic axial spondyloarthritis (r‐axSpA). SURPASS is the first head‐to‐head phase IIIb study comparing such changes in patients with r‐axSpA treated with secukinumab (IL‐17A inhibitor) versus adalimumab biosimilar (Sandoz adalimumab [SDZ‐ADL]; TNF inhibitor).MethodsBiologic‐naïve patients with active r‐axSpA, at high risk
-
Laser capture microscopy (LCM)‐RNAseq for topological mapping of synovial pathology during rheumatoid arthritis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-04-01 Benjamin Van Espen, E. Barton Prideaux, Andrew R. Wilson, Camilla R.L. Machado, Sho Sendo, James Parker, Grégory Seumois, Cristiano Sacchetti, Anna C. Belongia, Narayanan B. Perumal, Pandurangan Vijayanand, Matthew D. Linnik, Robert J. Benschop, Wei Wang, Nunzio Bottini, Gary S. Firestein, Stephanie M. Stanford
ObjectiveRheumatoid arthritis (RA) is an autoimmune disease in which the joint lining, or synovium, becomes highly inflamed and majorly contributes to disease progression. Understanding pathogenic processes in RA synovium is critical for identifying therapeutic targets. We performed laser capture microscopy (LCM) followed by RNA sequencing (LCM‐RNAseq) to study regional transcriptomes throughout RA
-
Increased interferon signalling in vaginal tissue of patients with primary Sjögren's syndrome. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Annie Visser, Jolien F van Nimwegen, Rick Wilbrink, Silvia C Liefers, Karin van der Tuuk, Marian J E Mourits, Gilles F H Diercks, Joost Bart, Bert van der Vegt, Léon C van Kempen, Hendrika Bootsma, Frans G M Kroese, Gwenny M Verstappen
Vaginal dryness is an important factor influencing sexual function in women with primary Sjögren's syndrome (pSS). Previous studies showed a higher degree of inflammation in vaginal biopsies from pSS patients compared to non-pSS controls. However, the molecular pathways that drive this inflammation remain unclear. Therefore, the aim of this study was to investigate inflammatory pathway activity in
-
School well-being and academic performance of children with juvenile idiopathic arthritis - a national register-based study. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Malthe Jessen Pedersen, Christian Høst, Stefan Nygaard Hansen, Jens Klotsche, Kirsten Minden, Bent Deleuran, Bodil Hammer Bech
We aimed to investigate how school well-being (SWB) and academic performance of children with juvenile idiopathic arthritis (JIA) compare to their peers on a national level using the Danish national registers. Further, we investigated the potential influence of socioeconomic status (SES).
-
The Duty to Accommodate. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Murray Baron
As the study by Jazayeri et al in this issue of The Journal of Rheumatology points out, the prevalence of unemployment in people with systemic sclerosis (SSc) is estimated at 40.5%, and SSc is associated with "presenteeism (ie, working while unwell), lack of participation in employment, and ultimately, absenteeism."1 This is of course true of patients with the many other musculoskeletal diseases that
-
Hospitalization and Mortality due to Infection among United States Children and Adolescents with Systemic Lupus Erythematosus. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Jordan E Roberts, Anna Faino, Mersine A Bryan, Jonathan D Cogen, Esi M Morgan
We aimed to determine the frequency and types of infections in hospitalized children with childhood-onset systemic lupus erythematosus (cSLE), and to identify risk factors for intensive care unit (ICU) admission and mortality.
-
Phase Specific Health Care Costs Associated with Giant Cell Arteritis in Ontario, Canada. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Mats Junek, Lillian Barra, Alexander Kopp, Tina Felfeli, Jodi Gatley, Jessica Widdifield
To estimate the additional health care system costs associated with giant cell arteritis (GCA) in the year pre-diagnosis, post diagnosis, and over long-term follow up compared to individuals with similar demographics and comorbidities without GCA.
-
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Ignacio Braña, Marta Loredo, Estefanía Pardo, Stefanie Burger, Eva Fernández-Bretón, Rubén Queiro
Information on the persistence of tofacitinib in PsA is scarce in real-life conditions. Our objective was to analyze persistence and safety of tofacitinib under these conditions.
-
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Daniel G Fernández-Ávila, Wilson Bautista-Molano, María Lorena Brance, María Gabriela Ávila Pedretti, Rubén Burgos Vargas, José Francisco Díaz Coto, Luis Arturo Gutiérrez, Marwin Gutiérrez, Enrique Giraldo Ho, Sebastián Eduardo Ibáñez Vodnizza, Edwin Jáuregui, Vanessa Ocampo, Penélope Esther Palominos, Daniel Ruben Palleiro Rivero, Guillermo Andrés Quiceno, Fernando Andrés Sommerfleck, Luis Enrique
Psoriatic arthritis (PsA) is chronic disease that compromise multiple domains, and might be associated with progressive joint damage, increased mortality, functional limitation, and considerably impaired quality of life. Our objective is to generate evidence-based recommendations on the management of PsA in PANLAR countries.
-
Lupus Nephritis Treatment Strategies. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Gabriel Nicolas Contreras Martin
Lupus nephritis (LN) is present in approximately 25% to 50% of patients at the time of systemic lupus erythematosus diagnosis and eventually develops in up to 60% of adults and 80% of children.1 Over the past 5 decades, major advances in immunosuppressive medications for patients with severe LN (classes III, IV, and V alone or in combination) have resulted in significant improvements in patient survival
-
Prevalence, predictors, and prognosis of serious infections in Takayasu arteritis - a cohort study. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Durga Prasanna Misra, Upendra Rathore, Swapnil Jagtap, Prabhaker Mishra, Darpan R Thakare, Kritika Singh, Tooba Qamar, Deeksha Singh, Juhi Dixit, Manas Ranjan Behera, Neeraj Jain, Manish Ora, Dharmendra Singh Bhadauria, Sanjay Gambhir, Vikas Agarwal, Sudeep Kumar
To describe the incidence, risk factors, and outcomes associated with serious infections in patients with Takayasu arteritis (TAK).
-
Association of Infant Breastfeeding and Spondyloarthritis: A Case-Control Study. J. Rheumatol. (IF 3.9) Pub Date : 2024-04-01 Katelyn Baggett, Timothy G Brandon, Rui Xiao, Pamela F Weiss
Given the multifactorial pathogenesis of juvenile spondyloarthritis (JSpA) and evidence of a protective effect in phenotypically similar diseases, we aimed to test whether breastfeeding is associated with the development and disease activity of JSpA.
-
Description of a novel splice site variant in UBA1 gene causing VEXAS syndrome Rheumatology (IF 5.5) Pub Date : 2024-03-29 Daniela Ospina Cardona, Ignasi Rodriguez-Pinto, Sonia Iosim, Nuria Bonet, Anna Mensa-Vilaro, Mei-Kay Wong, Gary Ho, Marc Tormo, Jordi Yagüe, Wonwoo Shon, Daniel Wallace, Ferran Casals, David B Beck, Rachel Abuav, Juan I Arostegui
Objective The vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a complex immune disorder consequence of somatic UBA1 variants. Most reported pathogenic UBA1 variants are missense or splice site mutations directly impairing the translational start site at p. Met41, with recent studies showing that these variants are frequent causes of recurrent inflammation in older individuals
-
Dual MPO/PR3 ANCA positivity and vasculitis: insights from a 7-cases study and an AI-powered literature review Rheumatology (IF 5.5) Pub Date : 2024-03-29 Eléonore Bettacchioli, Jean-Baptiste Foulquier, Baptiste Chevet, Emilie Cornec-Le Gall, Catherine Hanrotel, Luca Lanfranco, Claire de Moreuil, Yannick Lambert, Maryvonne Dueymes, Nathan Foulquier, Divi Cornec
Objectives Anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV) are rare conditions characterized by inflammatory cell infiltration in small blood vessels, leading to tissue necrosis. While most patients with AAV present antibodies against either myeloperoxidase (MPO) or proteinase 3 (PR3), rare cases of dual positivity for both antibodies (DP-ANCA) have been reported, and their